Quinupristin
Quinupristin is semisynthetic derivative of naturally occuring pristinamycins, produced by Streptomyces pristinaespiralis.It is a protein synthesis inhibitor that binds the 50 S ribosomal subunit with inhibition of polypeptide elongation and early termination of protein synthesis.Quinupristin is approved for treatment of infections caused by Vancomycin-resistant strains of E. faecium and complicated skin and skin structure infections caused by Methicillin resistant strains of S. aureuses or S. pyogens. Quinupristin should be reserved for the treatment of serious infections caused by multiple drug resistant gram-positive organisms such as vancomycin- resistant E.faecium.
Primary Characteristics
Non-proprietary name: Quinupristin.
Pharmacokinetics
Distribution: Quinupristin has a volume of distribution is 0.79(0.39-1.19)l/kg. plasma protein binding is 22.5(23-22)%.
Elimination: plasma half-life is 0.85 hr, renal excretion is 15.1%.
Advertisement
Indications
Quinupristin is primarily indicated in conditions like Extravasation/haematoma, Skin infections.
Contraindications
Quinupristin is contraindicated in conditions like Hypersensitivity to any component of product.
Dosage
None recorded.
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Quinupristin is known to cause more or less tolerable side effects which are usually transient. These include Arthralgia, Myalgia, Pain , Phlebitis .
Warnings / Precautions
Interference in Pathology
Quinupristin may interfere in the diagnosis of Increased level of Blood urea nitrogen (BUN) concentrations, Monitoring of ALT AND AST level, Increased concentration of creatinine kinase.
Available Brands
None recorded.
Drug Classification
- 1.6.2.1.4 — Other inhibitors of cell wall synthesis